drugset / Trial / NCT02746328

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

NCT02746328

Phase 2 Withdrawn GTx
NaSingle-groupOpen-labelTreatment

Summary

This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.

Timeline

Start
2016-04
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Enobosarm Small molecule 9 mg
Subject Enobosarm Small molecule 18 mg